Assessing Real-World Mobility Function Beyond Timed Walking Tests

By
Davide Liborio Vetrano
October 23, 2026

Jama Network Open

At a Glance

Category	Detail
Condition	Clinical topic addressed by the source article: Assessing Real-World Mobility Function Beyond Timed Walking Tests
Key Mechanisms	The article describes clinical walking speed as a measure that integrates multiple physiologic systems and may reflect physiologic reserve. It distinguishes standardized clinical walking capacity from free-living mobility, which is influenced by environment, habits, motivation, social participation, opportunity, and everyday demands.
Target Population	Population described in the source article.
Care Setting	A brief standardized clinical walking test and 9 days of free-living wrist-worn accelerometry.

Key Highlights

In 4067 Whitehall II participants, clinical walking speed and free-living cadence measures were each associated with lower all-cause mortality after adjustment.
The measures had broadly similar discriminative ability, but only clinical walking speed significantly improved discrimination beyond the fully adjusted risk model.
Clinical walking speed and free-living cadence were only modestly correlated, reflecting distinct assessment contexts.
The cohort was relatively high functioning and active: mean clinical walking speed was 1.2 m/s and average daily steps were approximately 9500.
The authors caution that the study provides limited evidence that combining clinical and free-living measures improves mortality discrimination.

Guideline-Based Recommendations

Diagnosis

The article describes clinical walking speed as a brief functional measure; it does not provide diagnostic criteria for a disease.

Management

The article does not provide treatment recommendations.

Monitoring & Follow-up

The study measured usual walking speed with a brief clinical walking test and free-living cadence using 9 days of wrist-worn accelerometry; these are study methods, not guideline recommendations.

Risks

The article discusses slower gait as potentially reflecting deficits across multiple physiologic systems and reduced physiologic reserve.
Study limitation: the relatively high-functioning cohort and healthier participants contributing accelerometer data may have constrained the measures’ ability to distinguish mortality risk.

Patient & Prescribing Data

The study included 4067 Whitehall II cohort participants; those contributing accelerometer data were healthier than the overall cohort.

No treatment or prescribing data are reported. The article discusses clinical walking speed and free-living cadence as mobility measures associated with mortality.